Experience:
No experience
Employment Type:
Intern/Co-op
Posted:
5/2/2019
Job Category:
Health Care Provider
Intern (Early Discovery Cancer Immunology)
(This job is no longer available)
Agenus | Lexington, MA
loading
loading
School
Major
Grad Date
 
 

Not sure what types of jobs you are interested in?


Explore Jobs
Based on Your Education

Follow This Company
Share

Job Description

The candidate will be responsible for generation, analysis and interpretation of standard biochemical assays such as ELISA. Other responsibilities may include maintenance of cell lines and assistance with pre-clinical studies in the mouse. As a part of the team, the candidate will participate in project meetings and will be required to maintain an electronic record of his/her activities. The candidate will also be responsible for attending weekly group meetings and present generated results. Agenus will provide the intern with the opportunity to gain valuable knowledge into drug discovery in a biotech environment and contribute to the development of innovative therapies.

Applicants should be 18 years or older and currently enrolled in a full time Bachelor's Degree program from an accredited college or university with a 3.0 minimum GPA . An eagerness, ability to work independently, and adaptability in a dynamic work environment are also necessary. Basic laboratory skills including cell culture handling, liquid pipetting technique, and vivarium experience are preferred.

About Agenus

Agenus is focused in the areas of oncology and infectious diseases. With our strong platform technologies, we have advanced multiple product candidates through the clinic and defined the most suitable patient populations to benefit from our novel vaccine approach. To advance our pioneering work in HSP-based vaccines, we are applying our technology to both autologous and non-autologous therapies. Agenus' licensees for QS-21 Stimulon® adjuvant include GlaxoSmithKline and Janssen Alzheimer Immunotherapy (a wholly owned subsidiary of Johnson & Johnson). QS-21 represents the most advanced adjuvant currently in clinical development. Agenus and NewVac LLC (a subsidiary of ChemRar High Tech Center and resident of the Skolkovo Innovation Center in Russia), a company focused on the development of innovative technology for cancer immunotherapy, have formed a license, development and manufacturing technology transfer agreement for Agenus' Oncophage® (HSPPC-96 ; vitespen) vaccine. Oncophage is approved in Russia for the treatment of renal cell carcinoma ("RCC"; kidney cancer) in patients at intermediate risk of recurrence. Under the agreement, Agenus has granted NewVac an exclusive license to manufacture, market and sell Oncophage as well as pursue a development program of Oncophage in combination with NewVac's co-adjuvant technology in the Russian Federation and CIS countries. Our business strategy is two pronged (1) to discover, develop and commercialize novel vaccines in our core therapeutic areas and (2) to partner and collaborate with leading institutions and companies in an effort to speed our product candidates to market. We recognize the importance of combining our expertise with those of our industry colleagues to help important medical discoveries reach patients and physicians faster. We are currently pursuing internal product development in both oncology and infectious diseases and we are actively pursuing a variety of partnership opportunities to augment our internal programs. Key benefits of working with Agenus include: Over 15 years of clinical development expertise Fully integrated research and development departments GMP manufacturing capabilities with experienced operations team Business development & commercial experience Public company infrastructure